Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial

• Main Authors: Leilani Sanchez (Author), Osamu Matsuoka (Author), Satoshi Inoue (Author), Takahiro Inoue (Author), Ya Meng (Author), Takahiro Nakama (Author), Kumiko Kato (Author), Aseem Pandey (Author), Lee-Jah Chang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A trivalent high-dose inactivated influenza vaccine has been licensed in healthy adults ≥65 years of age and provides better protection against influenza infection and related complications than trivalent standard-dose vaccine. This phase I/II clinical trial (NCT03233217), conducted at two sites in...